Alzheimer's disease (AD) is a progressive
neurodegenerative disorder characterized by
amyloid-β (Aβ) deposition and neurofibrillary tangles.
Dl-PHPB [
potassium 2-(1-hydroxypentyl)-
benzoate], has been shown to have
neuroprotective effects on cerebral ischemic,
vascular dementia, and Aβ-induced animal models by inhibiting oxidative injury, neuronal apoptosis, and glial activation. The aim of the present study was to examine the effect of
dl-PHPB on learning and memory in
amyloid precursor
protein (APP) and
presenilin 1 (PS1) double-transgenic AD mouse models (APP/PS1) and the mechanisms of
dl-PHPB in reducing Aβ accumulation and τ phosphorylation. Twelve-month-old APP/PS1 mice were given 30 mg/kg
dl-PHPB by oral gavage for 3 months.
Dl-PHPB treatment significantly improved the spatial learning and
memory deficits compared with the vehicle-treated APP/PS1 mice. In the meantime,
dl-PHPB obviously reduced τ hyperphosphorylation at Ser199, Thr205, and Ser396 sites in APP/PS1 mice. This reduction was accompanied by APP phosphorylation reduction and
protein kinase C activation. In addition, expression of
cyclin-dependent kinase and
glycogen synthase kinase 3β, the most important
kinases involved in τ phosphorylation, was markedly decreased by
dl-PHPB treatment. Phosphorylated
protein kinase B and
phosphoinositide 3-kinase levels of APP/PS1 mice were significantly reduced compared with levels in wild-type mice, and
dl-PHPB reversed the reduction. The effects of
dl-PHPB effecting a decrease in τ phosphorylation and
kinase activation were further confirmed in
neuroblastoma SK-N-SH cells overexpressing wild-type human APP695. These data raised the possibility that
dl-PHPB might be a promising multitarget neuronal
protective agent for the treatment of AD.